Posted on September 13, 2017 by Sitemaster
Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abirtaerone, ADT, hormone-sensitive, locally advanced, node-negative, node-positive, non-metastatic, outcome, STAMPEDE, survival | 7 Comments »
Posted on September 11, 2017 by Sitemaster
A presentation at the ongoing annual meeting of the European Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen deprivation, docetaxel, hormone-sensitive, metastatic, mHSPC | 4 Comments »
Posted on March 24, 2016 by Sitemaster
According to a media release issued today by Astellas Pharma and Medivation, the companies have just initiated a new, Phase III, pivotal trial of enzalutamide in men with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ARCHES, enzalutamide, hormone-sensitive, metaststic, trial | 4 Comments »
Posted on June 24, 2015 by Sitemaster
A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, advanced, androgen, deprivation, hormone-sensitive, progressive, statin | 3 Comments »
Posted on October 31, 2014 by Sitemaster
According to a joint media release from Medivation and Astellas earlier today, the companies will soon be initiating an important and major new trial of enzalutamide in men with progressive prostate cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", enzalutamide, hormone-sensitive, progressive | Leave a comment »
Posted on May 2, 2013 by Sitemaster
It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, orteronel, TAK-700 | 9 Comments »
Posted on July 15, 2011 by Sitemaster
The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, CTC, hormone, hormone-sensitive, metastatic, therapy | 2 Comments »
